AAAAAA

   
Results: 1-15 |
Results: 15
IL-6 upregulates its own receptor on some human myeloma cell lines
Authors: Thabard, W Collette, M Mellerin, MP Puthier, D Barille, S Bataille, R Amiot, M
Citation: W. Thabard et al., IL-6 upregulates its own receptor on some human myeloma cell lines, CYTOKINE, 14(6), 2001, pp. 352-356
Protein kinase C delta and eta isoenzymes control the shedding of the interleukin 6 receptor alpha in myeloma cells
Authors: Thabard, W Collette, M Bataille, R Amiot, M
Citation: W. Thabard et al., Protein kinase C delta and eta isoenzymes control the shedding of the interleukin 6 receptor alpha in myeloma cells, BIOCHEM J, 358, 2001, pp. 193-200
Interferon alpha extends the survival of human myeloma cells through an upregulation of the Mcl-1 anti-apoptotic molecule
Authors: Puthier, D Thabard, W Rapp, MJ Etrillard, M Harousseau, JL Bataille, R Amiot, M
Citation: D. Puthier et al., Interferon alpha extends the survival of human myeloma cells through an upregulation of the Mcl-1 anti-apoptotic molecule, BR J HAEM, 112(2), 2001, pp. 358-363
The role of interleukin-6 and interleukin-6/interleukin-6 receptor-alpha complex in the pathogenesis of multiple myeloma
Authors: Barille, S Bataille, R Amiot, M
Citation: S. Barille et al., The role of interleukin-6 and interleukin-6/interleukin-6 receptor-alpha complex in the pathogenesis of multiple myeloma, EUR CYTOKIN, 11(4), 2000, pp. 546-551
Soluble IL-6R alpha upregulates IL-6, MMP-1 and MMP-2 secretion in bone marrow stromal cells
Authors: Barille, S Collette, M Thabard, W Bleunven, C Bataille, R Amiot, M
Citation: S. Barille et al., Soluble IL-6R alpha upregulates IL-6, MMP-1 and MMP-2 secretion in bone marrow stromal cells, CYTOKINE, 12(9), 2000, pp. 1426-1429
Reactive plasmacytoses in multiple myeloma during hematopoietic recovery with G- or GM-CSF
Authors: Jego, G Avet-Loiseau, H Robillard, N Moreau, P Amiot, M Harousseau, JL Pellat-Deceunynck, C Bataille, R
Citation: G. Jego et al., Reactive plasmacytoses in multiple myeloma during hematopoietic recovery with G- or GM-CSF, LEUK RES, 24(7), 2000, pp. 627-630
Myeloma cells release soluble interleukin-6R alpha in relation to disease progression by two distinct mechanisms: Alternative splicing and proteolytic cleavage
Authors: Thabard, W Barille, S Collette, M Harousseau, JL Rapp, MJ Bataille, R Amiot, M
Citation: W. Thabard et al., Myeloma cells release soluble interleukin-6R alpha in relation to disease progression by two distinct mechanisms: Alternative splicing and proteolytic cleavage, CLIN CANC R, 5(10), 1999, pp. 2693-2697
Differential expression of Bcl-2 in human plasma cell disorders according to proliferation status and malignancy
Authors: Puthier, D Pellat-Deceunynck, C Barille, S Robillard, N Rapp, MJ Juge-Morineau, N Harousseau, JL Bataille, R Amiot, M
Citation: D. Puthier et al., Differential expression of Bcl-2 in human plasma cell disorders according to proliferation status and malignancy, LEUKEMIA, 13(2), 1999, pp. 289-294
Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment
Authors: Derenne, S Amiot, M Barille, S Collette, M Robillard, N Berthaud, P Harousseau, JL Bataille, R
Citation: S. Derenne et al., Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment, J BONE MIN, 14(12), 1999, pp. 2048-2056
Production of metalloproteinase-7 (matrilysin) by human myeloma cells and its potential involvement in metalloproteinase-2 activation
Authors: Barille, S Bataille, R Rapp, MJ Harousseau, JL Amiot, M
Citation: S. Barille et al., Production of metalloproteinase-7 (matrilysin) by human myeloma cells and its potential involvement in metalloproteinase-2 activation, J IMMUNOL, 163(10), 1999, pp. 5723-5728
IL-6 up-regulates Mcl-1 in human myeloma cells through JAK/STAT rather than Ras/MAP kinase pathway
Authors: Puthier, D Bataille, R Amiot, M
Citation: D. Puthier et al., IL-6 up-regulates Mcl-1 in human myeloma cells through JAK/STAT rather than Ras/MAP kinase pathway, EUR J IMMUN, 29(12), 1999, pp. 3945-3950
Mcl-1 and Bcl-x(L) are co-regulated by IL-6 in human myeloma cells
Authors: Puthier, D Derenne, S Barille, S Moreau, P Harousseau, JL Bataille, R Amiot, M
Citation: D. Puthier et al., Mcl-1 and Bcl-x(L) are co-regulated by IL-6 in human myeloma cells, BR J HAEM, 107(2), 1999, pp. 392-395
CD130 rather than CD126 expression is associated with disease activity in multiple myeloma
Authors: Barille, S Thabard, W Robillard, N Moreau, P Pineau, D Harousseau, JL Bataille, R Amiot, M
Citation: S. Barille et al., CD130 rather than CD126 expression is associated with disease activity in multiple myeloma, BR J HAEM, 106(2), 1999, pp. 532-535
Reactive plasmacytoses are expansions of plasmablasts retaining the capacity to differentiate into plasma cells
Authors: Jego, G Robillard, N Puthier, D Amiot, M Accard, F Pineau, D Harousseau, JL Bataille, R Pellat-Deceunynck, C
Citation: G. Jego et al., Reactive plasmacytoses are expansions of plasmablasts retaining the capacity to differentiate into plasma cells, BLOOD, 94(2), 1999, pp. 701-712
The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myeloma
Authors: Pellat-Deceunynck, C Barille, S Jego, G Puthier, D Robillard, N Pineau, D Rapp, MJ Harousseau, JL Amiot, M Bataille, R
Citation: C. Pellat-deceunynck et al., The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myeloma, LEUKEMIA, 12(12), 1998, pp. 1977-1982
Risultati: 1-15 |